2,955 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Biltmore Family Office LLC

Biltmore Family Office LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,955 shares of the company’s stock, valued at approximately $230,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD grew its holdings in shares of AstraZeneca by 17.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after buying an additional 9,002,450 shares during the period. Envestnet Asset Management Inc. increased its holdings in shares of AstraZeneca by 16.7% in the second quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after acquiring an additional 488,644 shares in the last quarter. Clearbridge Investments LLC increased its holdings in shares of AstraZeneca by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after acquiring an additional 186,010 shares in the last quarter. Swedbank AB acquired a new stake in shares of AstraZeneca during the first quarter worth about $186,127,000. Finally, Raymond James & Associates lifted its holdings in shares of AstraZeneca by 0.5% during the 2nd quarter. Raymond James & Associates now owns 2,576,736 shares of the company’s stock valued at $200,959,000 after purchasing an additional 13,396 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $64.13 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business has a 50-day moving average of $73.69 and a 200-day moving average of $77.86. The stock has a market capitalization of $198.83 billion, a price-to-earnings ratio of 30.68, a PEG ratio of 1.17 and a beta of 0.47. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the business posted $0.87 EPS. The business’s revenue was up 18.0% compared to the same quarter last year. As a group, sell-side analysts predict that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AZN shares. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, TD Cowen upped their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.